SynthesisFrontiers in cardiovascular medicine2026
Supraventricular tachyarrhythmias in arrhythmogenic cardiomyopathy and Brugada syndrome: a systematic review.
Synthesis in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Arrhythmogenic cardiomyopathy (ACM) and Brugada syndrome (BrS) are inherited arrhythmogenic disorders historically defined by their predisposition to ventricular arrhythmias and sudden cardiac death (SCD). Accumulating evidence indicates that both conditions also involve the atrial myocardium and are associated with a high prevalence of supraventricular tachyarrhythmias (SVT). A clearer understanding of their mechanisms and clinical impact is essential to optimize risk stratification and management. Methods: A systematic review was conducted in accordance with the PRISMA 2020 statement. PubMed and the Cochrane Library were searched up to December 2025 for studies reporting atrial fibrillation (AF), atrial flutter (AFL), atrioventricular nodal re-entrant tachycardia (AVNRT), or atrioventricular re-entrant tachycardia (AVRT) in patients with ACM or BrS. Of 487 records identified, 486 were screened after removal of one duplicate, and 30 studies met the inclusion criteria. Data on atrial substrate, SVT prevalence, mechanisms, and clinical outcomes were extracted. Results: SVT were consistently more frequent in both ACM and BrS than in age-matched general populations. AF was the most common arrhythmia, often arising at a young age and in structurally normal atria. Across studies, SVT were linked to inappropriate implantable cardioverter-defibrillator (ICD) shocks, heart failure progression, recurrence of ventricular arrhythmias, and an elevated thromboembolic risk that was frequently underestimated by the CHA₂DS₂-VASc score. Conclusions: SVT represent a clinically relevant manifestation of ACM and BrS and carry prognostic implications for arrhythmic monitoring, ICD programming, and thromboembolic risk assessment. Prospective studies are needed to refine risk-stratification tools and to clarify the mechanistic overlap between these inherited arrhythmogenic syndromes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.